Eli Lilly Weight Loss Competition

News

CEO of Novo Nordisk, Maker of Weight Loss Drug Wegovy

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Reuters on MSN · 20h

Novo Nordisk CEO's Surprise Exit After Setbacks in Weight-Loss Market

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer on the Novo Nordisk Board of Directors for election in 2026. The changes are without any changes to the company's strategy, according to Chairman Helge Lund."

CBS News on MSN · 18h

Novo Nordisk CEO, who led company into weight-loss drugs, to step down

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement."

12h

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

18don MSN

Eli Lilly Stock Gets a Double Downgrade. Where Weight-Loss Drugs Go From Here.

Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy ... Novo stock has been falling for much of the past year due to increased competition and ...

Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

29d

Eli Lilly Stock Soars on Oral Weight-Loss Drug Trial Results

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

ABC News16d

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit ...

13h

Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

19hon MSN

Novo Replaces CEO Jorgensen After Lilly Rivalry Hits Shares

Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...

Wellness companies eager to avoid WeightWatchers’ fate embrace weight-loss drugs

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

17hon MSN

Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

pharmaphorum5d

More data back Zepbound over Wegovy for weight loss

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results